98%
921
2 minutes
20
The optimization of absorption, distribution, metabolism, and excretion (ADME) profiles of compounds is critical to the drug discovery process. As such, machine learning (ML) models for ADME are widely used for prioritizing the design and synthesis of compounds. The effectiveness of ML models for ADME depends on the availability of high-quality experimental data for a diverse set of compounds that is relevant to the emerging chemical space being explored by the drug discovery teams. To that end, ADME data sets from Genentech and Roche were combined to evaluate the impact of expanding the chemical space on the performance of ML models, a first experiment of its kind for large-scale, historical ADME data sets. The combined ADME data set consisted of over 1 million individual measurements distributed across 11 assay end points. We utilized a multitask (MT) neural network architecture that enables the modeling of multiple end points simultaneously and thereby exploits information transfer between interconnected ADME end points. Both single- and cross-site MT models were trained and compared against single-site, single-task baseline models. Given the differences in assay protocols across the two sites, the data for corresponding end points across sites were modeled as separate tasks. Models were evaluated against test sets representing varying degrees of extrapolation difficulty, including cluster-based, temporal, and external test sets. We found that cross-site MT models appeared to provide a greater generalization capacity compared to single-site models. The performance improvement of the cross-site MT models was more pronounced for the relatively "distant" external and temporal test sets, suggesting an expanded applicability domain. The data exchange exercise described here demonstrates the value of expanding the learning from ADME data from multiple sources without the need to aggregate such data when the experimental methods are disparate.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acs.molpharmaceut.4c01086 | DOI Listing |
Nutr J
September 2025
Department of Life Sciences, Division of Food and Nutrition Science, Chalmers University of Technology, Gothenburg, 412 96, Sweden.
Background: Avenanthramides (AVAs) and Avenacosides (AVEs) are unique to oats (Avena Sativa) and may serve as biomarkers of oat intake. However, information regarding their validity as food intake biomarkers is missing. We aimed to investigate critical validation parameters such as half-lives, dose-response, matrix effects, relative bioavailability under single dose, and in relation to the abundance of Feacalibacterium prausnitzii, and under repeated dosing, to understand the potential applications of AVAs and AVEs as biomarkers of oat intake.
View Article and Find Full Text PDFClin Gastroenterol Hepatol
September 2025
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. Electronic address:
Background And Aims: Infliximab and ustekinumab clearance have been suggested as predictors of disease activity in patients with inflammatory bowel diseases. We aimed to investigate the benefits of clearance monitoring for predicting endoscopic outcomes in patients with Crohn's disease (CD).
Methods: Data from patients with moderate-to-severe CD starting infliximab (n=108) and ustekinumab (n=80) therapy were repurposed.
Adv Pharm Bull
July 2025
Department of Telecommunications & Systems Engineering, Universitat Autònoma de Barcelona, Sabadell, 08202, Spain.
Purpose: This study explores the potential of generative AI models to aid experts in developing scripts for pharmacokinetic (PK) models, with a focus on constructing a two-compartment population PK model using data from Hosseini et al.
Methods: Generative AI tools ChatGPT v3.5, Gemini v2.
Int J Pharm
September 2025
Department of Pharmaceutics, VCU School of Pharmacy, Richmond, VA 23298, USA. Electronic address:
Multiple exogenous supplements to achieve ketosis using the oral route have been developed to elevate blood BHB levels on demand and in a controllable fashion. The focus is now shifting to evaluating these supplements as potential therapeutic agents and developing strategies to not only achieve ketosis but also maintain it. One such strategy is to administer these as a continuous IV infusion.
View Article and Find Full Text PDFCrit Rev Ther Drug Carrier Syst
September 2025
Department of Pharmacology, PSG College of Pharmacy, Coimbatore 641004, Tamil Nadu, India.
Treating neurological disorders is challenging due to the blood-brain barrier (BBB), which limits therapeutic agents, including proteins and peptides, from entering the central nervous system. Despite their potential, the BBB's selective permeability is a significant obstacle. This review explores recent advancements in protein therapeutics for BBB-targeted delivery and highlights computational tools.
View Article and Find Full Text PDF